AVADEL PHARMACEUTICALS PLC — Operating Income by Fiscal Year

16 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/4372d318-36de-4ece-8051-c04a3edec90b/serie/operating-income

Fiscal year	Operating Income	Period	Evidence
FY 2024	$-42.4M	2024-01-01 – 2024-12-31	evidence 0001012477-25-000010
FY 2023	$-137.8M	2023-01-01 – 2023-12-31	evidence 0001012477-24-000008
FY 2022	$-98.6M	2022-01-01 – 2022-12-31	evidence 0001012477-23-000009
FY 2021	$-85.5M	2021-01-01 – 2021-12-31	evidence 0001012477-22-000004
FY 2020	$5.8M	2020-01-01 – 2020-12-31	evidence 0001012477-21-000004
FY 2019	$-24.1M	2019-01-01 – 2019-12-31	evidence 0001012477-20-000007
FY 2018	$-104.9M	2018-01-01 – 2018-12-31	evidence 0001012477-19-000002
FY 2017	$89.5M	2017-01-01 – 2017-12-31	evidence 0001012477-18-000008
FY 2016	$-5.0M	2016-01-01 – 2016-12-31	evidence 0001012477-17-000021
FY 2015	$70.8M	2015-01-01 – 2015-12-31	evidence 0001012477-17-000021
FY 2014	$-93.7M	2014-01-01 – 2014-12-31	evidence 0001012477-17-000021
FY 2013	$-53.7M	2013-01-01 – 2013-12-31	evidence 0001144204-15-026535
FY 2012	$-9.9M	2012-01-01 – 2012-12-31	evidence 0001144204-15-026535
FY 2011	$-9.6M	2011-01-01 – 2011-12-31	evidence 0001144204-12-024442
FY 2010	$-9.8M	2010-01-01 – 2010-12-31	evidence 0001144204-12-024442
FY 2009	$-11.8M	2009-01-01 – 2009-12-31	evidence 0001144204-12-024442

Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

AVADEL PHARMACEUTICALS PLC — all facts · Revenue · Net Income